NCT00000948View on ClinicalTrials.gov

Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 28, 1998

Primary Completion Date

March 31, 2000

Conditions
HIV Infections
Interventions
DRUG

Aldesleukin

Il-2

DRUG

ART

antiretroviral therapy for the treatment of HIV

Trial Locations (2)

Unknown

Chulalongkorn Univ. Hosp. C603-010 CRS, Bangkok

Siriraj Hospital C603-020 CRS, Bangkok

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000948 - Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 | Biotech Hunter | Biotech Hunter